COMPANY OVERVIEW

Lycera is a private biopharmaceutical company that is developing novel small molecule immunomodulatory medicines for the treatment of autoimmune diseases and cancer. Based on its world-class R&D engine, Lycera is advancing clinical candidates from distinct, yet complementary , areas of research, including immune metabolism, cell signaling, and immune cell differentiation.

---

LOCATION

New York, NY, USA

Ann Arbor, MI, USA

Plymouth Meeting, PA, USA

---

THERAPEUTIC AREAS

Autoimmune Disease

Oncology

---

WEBSITE

https://lycera.com

---

CAREER WEBSITE

https://www.lycera.com/careers

---

SOCIAL MEDIA

---

INVESTORS

---

---

PRESS RELEASES

Oct 10, 2018

Lycera Announces Presentations at the 2018 ESMO Congress for LYC-55716, a First-in-class RORgamma Agonist Candidate

May 30, 2018

Lycera to Present on First-in-class RORgamma Agonist Candidate LYC-55716 at the 2018 ASCO Annual Meeting

May 16, 2018

Lycera Announces Publication of Preclinical Immuno-Oncology Research, Demonstrating that Treatment with RORgamma Agonists Enhances CAR T-Cell Anti-Tumor Activity and Persistence, Resulting in Long-Lasting Anti-Tumor Memory T-Cells in an In Vivo Model

Apr 17, 2018

Lycera Presents Clinical Safety and Dose Selection Results for First-in-class RORgamma Agonist Candidate LYC-55716 at the 2018 AACR Annual Meeting

Apr 5, 2018

Lycera to Present Clinical Results and Supporting Preclinical Data for First-In-Class RORgamma Agonist LYC-55716 at the 2018 AACR Annual Meeting

For More Press Releases

---